ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 759

Polymyalgia Rheumatica Patients with and Without Elevated Baseline Acute Phase Reactants: Distinct Subgroups of Polymyalgia Rheumatica?

Diane Marsman1, Aatke van der Maas 1, Alfons den Broeder 1, Nathan den Broeder 1, Nadine Boers 2 and Frank van den Hoogen 1, 1Sint Maartenskliniek, Nijmegen, Netherlands, 2Sint Maartenskliniek, Nijmegen

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: polymyalgia rheumatica

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic signs of inflammation such as raised CRP or ESR are a classical feature of PMR, but some patients present with normal acute phase reactants (APR).1,2 It is not known whether these patients represent milder forms of PMR, whether their disease is not yet fully expressed, or whether they represent another disease entirely. We will explore baseline differences in demographics and clinical characteristics in PMR patients with and without elevated APR to evaluate whether they are distinct subgroups of PMR.

Methods: We conducted a retrospective cohort study of newly diagnosed PMR patients (clinical diagnosis) who visited our outpatient clinic between April 2012 and September 2017. Patient with concomitant inflammatory rheumatic disease were excluded. Data on patient-, disease,- and treatment characteristics were extracted from the electronic health record. Descriptive statistics were used [mean (SD), median (p25-p75) or n (%) as appropriate], and differences between patients with normal versus high APR(CRP >10 mg/L and/or ESR >30mm/hour) were tested using Fischer’s exact test for categorical data, t-test for normally and Wilcoxon test for non-normally distributed data.

Results: 454 patients were included (table 1). Sixty-two patients had normal, and 392 had elevated APR. Fewer patients with normal APR had peripheral arthritis (2 versus 9 %; p=0.044) and anemia at diagnosis (17 versus 43%;p=0.001). Furthermore, patients had a longer median duration of symptoms before diagnosis (13 versus 10 weeks; p=0.02) and were more likely to have a history of PMR (16 versus 8 %;p=0.057). Patients with normal APR had a shorter median time to referral general practitioner due to GC-free remission (552 versus 693 days; n= 36 versus 160;p=0.023). In both groups flares occurred more often between 12-24 versus < 12 months compared to the first 12 months (35 versus 13%; p=0.001 and 30 versus 20%;p=0.010 in normal and elevated APR group respectively). Fewer patients with normal APR were prescribed methotrexate; 3 versus 12%;p=0.046).

Conclusion: The results of this cohort suggest that patients with normal APR are a somewhat milder subset of PMR patients and have a better prognosis. However, flare risk does not differ from APR positive patients.

Baseline characteristics of patients with normal versus elevated APR

Follow-up characteristics


Disclosure: D. Marsman, None; A. van der Maas, None; A. den Broeder, AbbVie, 9, Amgen, 8, Biogen, 9, BMS, 8, Boehringer Ingelheim, 8, Cellgene, 9, Fresenius, 8, Roche, 9; N. den Broeder, None; N. Boers, None; F. van den Hoogen, AbbVie, 5, Actelion, 2, Amgen, 8, Biogen, 5, BMS, 2, Boehringer Ingelheim, 5, Celgene, 5, Celltrion Healthcare, 5, 8, Corbus, 8, Eli Lily, 2, Janssen, 8, Mundipharma, 5, Novartis, 5, Pfizer, 2, Roche, 8, Sandoz, 8, Sanofi Genzyme, 5.

To cite this abstract in AMA style:

Marsman D, van der Maas A, den Broeder A, den Broeder N, Boers N, van den Hoogen F. Polymyalgia Rheumatica Patients with and Without Elevated Baseline Acute Phase Reactants: Distinct Subgroups of Polymyalgia Rheumatica? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/polymyalgia-rheumatica-patients-with-and-without-elevated-baseline-acute-phase-reactants-distinct-subgroups-of-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/polymyalgia-rheumatica-patients-with-and-without-elevated-baseline-acute-phase-reactants-distinct-subgroups-of-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology